ClinicalTrials.gg
CompletedNCT00378482Updated Aug 22, 2024Results posted

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

A Phase 2 interventional study of CP-675,206 (Tremelimumab) in Colorectal Neoplasms, Melanoma and Prostatic Neoplasms, sponsored by AstraZeneca. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing tremelimumab in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. tremelimumab · Colorectal Neoplasms.

Enrollment
6th of 14
37 · median 34
Started
2007
the only one that year
Phase 2
8 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
AstraZeneca

Among the 14 studies testing tremelimumab in Colorectal Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 2, and was the 2nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies testing tremelimumab in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tremelimumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

03

Conditions studied

  • Colorectal Neoplasms
  • Melanoma
  • Prostatic Neoplasms
  • Renal Cell Carcinoma
  • Neoplasms
  • Patients Who Have/Have Had Melanoma and Other Tumors

Keywords

  • Melanoma and other tumors
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must have already received tremelimumab in another protocol
  • Females of must agree to practice a form of effective for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator.
  • Subject must be willing and able to provide written and to comply with scheduled visits and other trial procedures

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    1

    Drug: CP-675,206 (Tremelimumab)

    Drug: CP-675,206 (Tremelimumab)

Interventions

  • 15 mg/kg IV every 3 months as long as required

    Also known as: anti-CTLA4 human monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Safety Endpoints: Serious Adverse Events to Tremelimumab.

    Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.

  2. Safety Endpoints: Grade 3 or 4 Tremelimumab-related Adverse Events to Tremelimumab.

    Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.

  3. Safety Endpoints: Hypersensitivity Reactions to Tremelimumab.

    Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.

  4. Efficacy Endpoints: Tumor Status: Alive With Disease (AWD) or no Evidence of Disease (NED)

    Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.

  5. Efficacy Endpoints: Survival

    Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.

Secondary outcomes

  1. Disease Free Survival

    Time from the first dose of study drug to the earliest date of evidence of disease (based on tumor status assessment) or death, whichever occurred first

    Time frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.

07

Results

Posted May 28, 2021

Participant flow

First subject enrolled: 05 Mar 2007; Data Cut-off: 18 Jun 2020. This was a multicenter study conducted at 11 study centers in 3 countries (the United Kingdom, the United States of America and Italy).

Participant flow — Overall Study
MilestoneTremelimumab 15mg/kg
Started37
Completed6
Not completed31
Withdrew: Lost to follow-up1
Withdrew: Lack of efficacy8
Withdrew: Subject or physician decision, or subject relocation to another city or region.9
Withdrew: Withdrawal by subject4
Withdrew: Adverse event9

Outcome measures

PrimarySafety Endpoints: Serious Adverse Events to Tremelimumab.
Time frame:
Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Reported as:
Count of participants · Participants
Safety Endpoints: Serious Adverse Events to Tremelimumab.
ParticipantsTremelimumab 15mg/kg
Number of Participants with SAE to tremelimumab4
Number of Participants with no SAE to tremelimumab33
PrimarySafety Endpoints: Grade 3 or 4 Tremelimumab-related Adverse Events to Tremelimumab.
Time frame:
Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Reported as:
Count of participants · Participants
Safety Endpoints: Grade 3 or 4 Tremelimumab-related Adverse Events to Tremelimumab.
ParticipantsTremelimumab 15mg/kg
Number of participants with Grade 3 or 4 tremelimumab-related adverse events to tremelimumab4
Number of participants with no Grade 3 or 4 tremelimumab-related adverse events to tremelimumab33
PrimarySafety Endpoints: Hypersensitivity Reactions to Tremelimumab.
Time frame:
Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Reported as:
Count of participants · Participants
Safety Endpoints: Hypersensitivity Reactions to Tremelimumab.
ParticipantsTremelimumab 15mg/kg
Number of participants with Hypersensitivity reactions to tremelimumab6
Number of participants with no Hypersensitivity reactions to tremelimumab31
PrimaryEfficacy Endpoints: Tumor Status: Alive With Disease (AWD) or no Evidence of Disease (NED)
Time frame:
Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Reported as:
Count of participants · Participants
Efficacy Endpoints: Tumor Status: Alive With Disease (AWD) or no Evidence of Disease (NED)
ParticipantsTremelimumab 15mg/kg
No evidence of disease19
Evidence of disease17
Indeterminate1
PrimaryEfficacy Endpoints: Survival
Time frame:
Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Reported as:
Count of participants · Participants
Efficacy Endpoints: Survival
ParticipantsTremelimumab 15mg/kg
Death10
Censored27
SecondaryDisease Free Survival

Time from the first dose of study drug to the earliest date of evidence of disease (based on tumor status assessment) or death, whichever occurred first

Time frame:
Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years.
Reported as:
Median · Days
Disease Free Survival
DaysTremelimumab 15mg/kg
Disease Free Survival3.0 (2.9 to 11.8)

Adverse events

Collected over 13 years, 3 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tremelimumab 15mg/kg11/37 (29.7%)4/37 (10.8%)5/37 (13.5%)
Most frequent serious events
Most frequent serious events
EventTremelimumab 15mg/kg
DiarrheaGastrointestinal disorders1/37
Medical Device ComplicationGeneral disorders1/37
CholecystitisHepatobiliary disorders1/37
SepsisInfections and infestations1/37
Urinary Tract InfectionInfections and infestations1/37
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/37
Pulmonary GranulomaRespiratory, thoracic and mediastinal disorders1/37
Most frequent other events
Most frequent other events
EventTremelimumab 15mg/kg
RashSkin and subcutaneous tissue disorders4/37
PruritusSkin and subcutaneous tissue disorders3/37
HypothyroidismEndocrine disorders2/37

Baseline characteristics

One participant received no study medication and was excluded from data analysis

Age, Categorical
Age, Categorical(Participants)Tremelimumab 15mg/kg
<=18 years0
Between 18 and 65 years24
>=65 years13
Sex: Female, Male
Sex: Female, Male(Participants)Tremelimumab 15mg/kg
Female11
Male26
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tremelimumab 15mg/kg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White37
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Newecastle Upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2007 to primary completion in Oct 2023, 199 months.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 199 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2006
First posted
Sep 20, 2006
StartActual
Mar 5, 2007
Primary completionActual
Oct 27, 2023
CompletionActual
Oct 27, 2023
Results first posted
May 28, 2021
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00378482
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 20, 2006
Start date
Mar 5, 2007
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023
Results posted
May 28, 2021
Last update
Aug 22, 2024

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
Peter Langmuir, Dir.Medic.Science
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion